Amgen, J&J EPO Study Proposals On Tumor Progression To Be Reviewed By Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oncologic Drugs Advisory Committee will discuss the adequacy of the study proposals. The companies maintain that erythropoietin, when used for labeled indications, is not associated with an increased risk of mortality.